BACKGROUND: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent...
-
November 23, 2018 (v1)Journal articleUploaded on: March 8, 2024
-
June 2021 (v1)Journal article
International audience
Uploaded on: December 3, 2022 -
March 2015 (v1)Journal article
International audience
Uploaded on: December 3, 2022 -
February 2020 (v1)Journal article
International audience
Uploaded on: December 3, 2022 -
September 1, 2015 (v1)Journal article
Purpose The aim of this randomized, phase II trial was to explore the activity and safety of adding bevacizumab to paclitaxel once per week in treatment of angiosarcomas (AS). Methods Patients were treated with paclitaxel alone (90 mg/m 2 per week for six cycles of 28 days each; arm A) or with paclitaxel combined with bevacizumab (10 mg/kg once...
Uploaded on: December 3, 2022 -
October 2018 (v1)Journal article
PurposeThe objective of this study was to describe the outcome and prognostic factors for adults treated for localized myxofibrosarcoma.Methods and MaterialsWe conducted a retrospective multicenter study of 425 nonmetastatic patients who underwent surgery between January 1996 and December 2015 in French National Group and were enrolled in the...
Uploaded on: December 4, 2022 -
June 28, 2018 (v1)Journal article
Five-year overall survival (OS) of localized RMS exceeds 70% in children (<18) but is very poor in adult patients. We analyzed the outcome and prognostic factors (PF) of a national series of adult patients with RMS in a large study. The study population consisted of two different cohorts: a retrospective cohort (157 adult patients treated in 13...
Uploaded on: December 4, 2022